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Abstract
Introduction Systemic lupus erythematosus (SLE) is a multi-
system autoimmune disease with a heterogeneous course and
varying degrees of severity and organ damage; thus, there is
increasing interest in identifying biomarkers for SLE. In this study
we correlated the combined expression level of multiple
interferon-inducible chemokines with disease activity, degree of
organ damage and clinical features in SLE, and we investigated
their roles as biomarkers.
Methods Peripheral blood cells obtained from 67 patients with
SLE patients, 20 patients with rheumatoid arthritis (RA) and 23
healthy donors were subjected to real-time PCR in order to
measure the transcriptional levels of seven interferon-inducible
chemokines (RANTES, MCP-1, CCL19, MIG, IP-10, CXCL11,
and IL-8). The data were used to calculate a chemokine score
for each participant, after which comparisons were performed
between various groups of SLE patients and control individuals.
Results Chemokine scores were significantly elevated in SLE
patients versus RA patients and healthy donors (P = 0.012 and
P = 0.002, respectively). Chemokine scores were correlated
positively with SLE Disease Activity Index 2000 scores (P =
0.005) and negatively with C3 levels (P < 0.001). Compared
with patients without lupus nephritis and those with inactive
lupus nephritis, chemokine scores were elevated in patients with
active lupus nephritis, especially when their daily prednisone
dosage was under 30 mg (P  = 0.002 and P  = 0.014,
respectively). Elevated chemokine scores were also associated
with the presence of cumulative organ damage (Systemic Lupus
International Collaborating Clinics/American Society of
Rheumatology Damage Index ≥ 1; P  = 0.010) and the
occurrence of anti-Sm or anti-RNP autoantibodies (both P =
0.021).
Conclusions The combined transcription level of interferon-
inducible chemokines in peripheral blood leucocytes is closely
associated with disease activity, degree of organ damage, and
specific autoantibody patterns in SLE. The chemokine score
may serve as a new biomarker for active and severe disease in
SLE.
Introduction
Systemic lupus erythematosus (SLE) is a multi-system autoim-
mune disease characterized by immune dysregulation that
results in the production of antinuclear and other autoantibod-
ies, as well as immune complex deposition in the kidneys and
other organs. The disease course of SLE is heterogeneous
CCL: C-C chemokine ligand; CXCL: C-X-C chemokine ligand; IFIG: IFN-inducible gene; IFIT: interferon-induced protein with tetratricopeptide 
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and characterized by unpredictable flares and remissions.
Thus, there is a pressing need to identify biomarkers that will
facilitate better assessment of disease activity and organ
involvement, and provide insight into the relationships
between pathogenesis and clinical manifestations.
Recently, we and others have used gene expression microar-
rays to identify a group of type I IFN-inducible genes (IFIGs)
that are significantly upregulated in peripheral blood cells from
SLE patients [1-4]. The expression of these IFIGs, often
referred to as IFN signatures, was later found to be closely
associated with increased disease activity, specific autoanti-
body profiles and significant organ damage in SLE patients
[5,6]. In addition to carrying markers of the IFN signature,
peripheral blood cells from SLE patients are also elevated in a
variety of chemokines [7]. Chemokines are a group of small
molecules with the ability to recruit specific leucocytes to tar-
get tissue sites, thereby contributing to the organ damage
seen in SLE. Other functions of chemokines include their abil-
ity to influence dendritic cell maturation, induction of B-cell and
T-cell development, determination of peripheral cell localiza-
tion, and involvement in T-helper-1 and T-helper-2 polarization
[8].
A number of studies have identified increased plasma concen-
trations of chemokines, including 'regulated upon activation
normal T-cell expressed and secreted' (RANTES), monocyte
chemotactic protein (MCP)-1, IL-8, IFN-inducible protein 10
(IP-10), and monokine induced by IFN-γ (MIG), in patients with
active SLE [9-12]. In addition, the ex vivo production of chem-
okines by peripheral blood cells from SLE patients appears to
be significantly higher than that of cells from normal control
individuals, after stimulation by lipopolysaccharide or phyto-
haemagglutinin [10], which suggests that the elevated expres-
sion of chemokines is involved in the immune dysregulation
seen in this disorder.
Although the contributions made by chemokines in the patho-
genesis of SLE have been studied extensively, the mecha-
nisms that give rise to the increased chemokine responses in
peripheral blood cells from SLE patients remain unclear. It has
been reported that certain chemokine responses are strongly
dependent upon IL-2 [13]. Another study [10] revealed that
the plasma concentrations of IP-10 and MIG are significantly
correlated with that of IL-18. A recent study [9] found that sev-
eral serum chemokines were significantly elevated in SLE
patients with increased expression of IFIGs, implying that the
production of certain chemokines may be regulated by the
type I IFN pathway. It is also interesting that IFN-inducible
chemokines are significantly elevated in active SLE patients, a
fact that raises the possibility that they might serve as novel
biomarkers for SLE disease activity, and which adds a new link
between these two essential aspects of SLE pathogenesis.
However, the associations between the IFN-inducible chem-
okines and the clinical features of SLE have not been fully
studied. Moreover, the finding that IFN-inducible chemokines
may serve as a biomarker in active SLE requires verification in
a larger cohort of patients, as well as in patients from different
races and backgrounds.
In the present study we measured the transcription levels of
seven IFN-inducible chemokines, as well as those of five clas-
sical IFIGs, in peripheral blood cells drawn from 67 patients
with SLE, 20 with rheumatoid arthritis (RA), and 23 healthy
donors, and calculated a chemokine score and an IFN score
for each participant. We found that the transcriptional levels of
IFN-inducible chemokines in peripheral blood cells were
closely associated with disease activity and organ damage in
SLE, and may be useful in disease monitoring and
prognostication.
Materials and methods
Patients and control individuals
This study was approved by the Review Board for RenJi Hos-
pital inShanghai, Republic of China. Informed consent was
obtained from all study participants. All studies were per-
formed in accordance with the Declaration of Helsinki. Sixty-
seven Chinese patients with SLE, 20 with RA, and 23 age-
matched and sex-matched healthy donors were enrolled in the
study (Table 1). The SLE and RA patients fulfilled the classifi-
cation criteria of the American College of Rheumatology for
SLE [14] and RA [15], respectively. All SLE and RA patients
were recruited from the Lupus Clinic Center of RenJi Hospital,
Shanghai JiaoTong University School of Medicine. Healthy
donors were selected from a pool of healthy volunteers at the
RenJi Hospital, aiming to match them to the lupus patients with
respect to age and sex. Otherwise eligible individuals with a
current or recent infection were excluded from the study.
The lupus patients were all receiving steroid therapy at the
time of the study, with an average prednisone (or equivalent)
dosage of 40 mg/day. In addition, 28 patients were taking
immunosuppressive therapy and 28 were receiving an antima-
larial drug (hydrochloroquine 200 to 400 mg/day). For each
patient, disease activity and disease-related damage were
assessed at the time of blood donation using the SLE Disease
Activity Index 2000 (SLEDAI-2K) [16] and the Systemic Lupus
International Collaborating Clinics/American College of Rheu-
matology Damage Index (SDI) [17].
Sample handling and RNA processing
Peripheral blood samples donated by each participant were
collected in tubes containing anticoagulant-citrate-dextrose
solution A. After plasma was collected, erythrocytes were
lysed immediately and total RNA extracted from leucocytes
using Trizol Reagent (Invitrogen, Carlsbad, CA, USA). Traces
of DNA contamination were routinely removed by On-column
DNase treatment using RNeasy Mini Kit (Qiagen, Hamburg,
Germany). The integrity of RNA was assessed using capillary
gel electrophoresis, and the quality and quantity of RNA wereAvailable online http://arthritis-research.com/content/10/5/R112
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measured using NanoDrop™ 1000 Spectrophotometer (Nan-
oDrop Technologies, Wilmington, DE, USA) with 260 nm/280
nm ratio above 1.8. About 1 μg total RNA was then reverse
transcribed into cDNA using SuperScript II Reverse Tran-
scriptase (Invitrogen). All plasma, RNA and cDNA samples
were stored at -70°C before use.
Real-time PCR
To quantify the expression of genes encoding IFN-inducible
chemokines and IFIGs, the transcriptional levels of a total of
seven IFN-inducible chemokine genes (RANTES, MCP-1,
MIG, IP-10, C-X-C chemokine ligand [CXCL]11, IL-8, and C-
C chemokine ligand [CCL]19) and five IFIGs (IFN-induced
protein with tetratricopeptide repeats [IFIT]1, IFIT3, myxovirus
resistance 1 [Mx1], oligoadenylate synthetase [OAS]1, and
lymphocyte antigen 6 complex, locus E [Ly6e]) were meas-
ured by real-time PCR using SYBR Green. All cDNA samples
were amplified in duplicate using Premix Ex Taq™ (Takara,
Shiga, Japan), with the expression of ribosomal protein L13a
used as an internal control for each sample. Details of the
method were described previously [2,18]. Primer sequences
are given in Table 2.
Calculation of chemokine scores and IFN scores
IFN scores were calculated as described in previous studies
[5,6]. The mean and standard deviation (SD) for the expres-
sion level of each IFIG in the healthy donor group (meanHD and
SDHD, respectively) were used to obtain a standardized
expression level (S) of each gene for each SLE patient, as fol-
lows: S = (GeneSLE - GeneHD)/SD (GeneHD). In this equation,
GeneSLE is the expression level of a particular gene in a given
SLE patient and GeneHD is the mean level of this gene in
healthy donors. All of the standardized expression level values
were summed to calculate a total IFN expression score for
each participant [5]. A chemokine score for each participant
was calculated in a similar manner.
Statistical analysis
Data were analyzed using the SPSS software for Windows
(Version 11.0; SPSS Inc., Chicago, IL, USA). The continuous
variable data were not normally distributed because of the
extremely elevated expression of IFIGs and chemokines in par-
ticular patients; consequently, all values were expressed as
medians with 25th and 75th percentiles and interquartile
ranges (IQRs), and comparisons were conducted using the
nonparametric Mann-Whitney test. Correlations between
groups were evaluated using the Spearman test. P  values
under 0.05 were considered statistically significant.
Results
Increased average chemokine score in SLE patients
The expression of seven IFN-inducible chemokine genes
(RANTES, MCP-1, MIG, IP-10, CXCL11, IL-8 and CCL19)
and five classic IFIGs (IFIT1, IFIT3, Mx1, OAS1 and Ly6e) in
peripheral blood cells from 67 SLE patients, 20 RA patients
and 23 healthy donors were measured using real-time reverse
transcription PCR. SLE patients, RA patients, and healthy
donors did not differ significantly with respect to mean age or
sex distribution (Table 1). In general, the lupus patients had
moderate disease activity and severity, with a mean SLEDAI-
2K score of 8.06 and mean SDI of 0.82 (Table 1). As shown
in Figure 1a, SLE patients had significantly higher chemokine
scores than did either RA patients or healthy donors (P =
0.012 and P = 0.002, respectively). There was no increase in
chemokine score in RA patients relative to healthy donors;
however, when classic IFN scores were considered, there
were no significant differences between the SLE and RA
patients, although the scores from both groups were notably
elevated compared with those of healthy donors (P < 0.001;
Figure 1b). In addition, chemokine scores were significantly
correlated with IFN scores in SLE patients (P = 0.040; Figure
1c). These data demonstrated relatively coordinated chemok-
ine and IFN scores in SLE patients but a discrepancy between
the scores in RA patients.
Table 1
Demographics of SLE and RA patients and healthy donors
SLE patients (n = 67) RA patients (n = 20) Healthy donors (n = 23)
Age (years) 35.43 ± 1.85 (14–60) 37.2 ± 1.68 (17–61) 32.21 ± 2 (16–58)
Sex (%)
Female 89.6 85 83.3
Male 10.4 15 16.7
Disease duration (years) 5.58 ± 0.75 (0.04–24) 5.93 ± 1.3 (1.2–21) -
ANA (%) 95.5 37.1 -
SLEDAI-2K 8.06 ± 0.68 (0–25) - -
SDI 0.82 ± 0.17 (0–6) - -
Except where otherwise indicated, values are expressed as mean ± standard error of the mean (range). There were no significant differences 
between patients with SLE, patients with RA and healthy donors in terms of age and sex. ANA, antinuclear antibody; RA, rheumatoid arthritis; SDI, 
Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SLE, systemic lupus erythematosus; 
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Correlation of chemokine score with disease activity, as 
assessed using SLEDAI-2K and hypocomplementaemia
To investigate whether the expression of IFN-inducible chem-
okines might be related to SLE disease activity, we compared
chemokine scores in SLE patients with different levels of dis-
ease activity, as assessed using SLEDAI-2K and the level of
complement C3. SLE patients were divided into those with
stable disease (SLEDAI-2K score 0 to 4), those with a mild
flare (SLEDAI-2K score 5 to 10) and those with a moderate to
severe disease flare (SLEDAI-2K score > 10), in accordance
with the SLEDAI-2K flare system. We found that chemokine
scores were significantly greater in SLE patients with a mod-
erate to severe flare of disease than in patients without a flare
(P = 0.029; Figure 2a). Chemokine scores were positively cor-
related with SLEDAI-2K scores (r = 0.34, P < 0.005; Figure
2b). C3 level is also an indicator of disease activity, with a low
C3 level often observed in SLE patients with active disease.
SLE patients with low C3 levels in the present study had a
notably higher mean chemokine score than did those with nor-
mal C3 (P = 0.007; Figure 2c). Further analysis identified a
negative correlation between chemokine scores and C3 level
(r = 0.41, P < 0.001) (Figure 2d). The IFN score also exhibited
notable correlations with SLEDAI-2K score and C3 level.
However, it appeared not to attain the same level of signifi-
cance as the chemokine score (P = 0.023 versus P < 0.005
and P = 0.016 versus P < 0.001, respectively; Figure 2e,f).
When other indicators of disease activity were considered, the
chemokine and IFN scores were not significantly correlated
with ESR or circulating levels of IgG anti-dsDNA antibody
(data not shown). There were no differences in the mean value
of chemokine scores between SLE patients with or without
rash or arthritis (Table 3).
Elevated chemokine scores in SLE patients with organ 
damage
Given that chemokines are involved in tissue damage and
inflammation, we next explored whether chemokine scores are
related to organ damage in SLE patients. Lupus nephritis (LN)
is one of the most serious manifestations of SLE. In our cohort,
nearly 55% of patients had either previous or current LN.
Patients were considered to have active renal disease if pro-
teinuria was above 0.5 mg/day, haematuria was above 5 red
blood cells per high-power field, pyuria was above 5 white
blood cells/high-power field, or cellular casts were present.
Infection, kidney stones, or other causes of these urine find-
ings were excluded. Chemokine scores among SLE patients
with active LN exhibited a positive trend toward elevation ver-
sus those without LN (P = 0.05), but the same trend was not
evident (P = 0.34) in a comparison against those with inactive
LN (Figure 3a).
Because prednisone may impair the expression of IFIGs by
peripheral blood cells[5], medication used by patients at the
time of blood donation could interfere with current results.
Consequently, in order to limit the potential influence of high-
dose prednisone on chemokine expression, we then selected
SLE patients taking daily prednisone doses less than 30 mg to
examine further the association between chemokine scores
and renal manifestations. As shown in Figure 3b, in these sub-
Table 2
Primers used to amplify transcripts of chemokines and IFIGs
Gene Forward Reverse
RPL13A 5'-CTGGAGGAGAAGAGGAAAGA-3' 5'-TTGAGGACCTCTGTGTATTTGTCA-3'
Ly6e 5'-CTTACGGTCCAACATCAGAC-3' 5'-GCACACATCCCTACTGACAC-3'
OAS-1 5'-GAAGGCAGCTCACGA AAC-3' 5'-TTCTTAAAGCATGGGTAATTC-3'
Mx1 5'-GGGTAGCCA CTGGACTGA-3' 5'-AGGTGGAGCGATTCTGAG-3'
IFIT1 5'-TCAAAGTCAGCAGCCAGTCTCA-3' 5'-GCCTCCTTGGGTTCGTCTATAA-3'
IFIT3 5'-AACTACGCCTGGGTCTACTATCACTT-3' 5'-GCCCTTTCATTTCTTCCACAC-3'
RANTES 5'-CGCTGTCATCCTCATTGCTAC-3' 5'-GGGTGACAAAGACGACTGCT-3'
MCP-1 5'-CATTGTGGCCAAGGAGATCTG-3' 5'-CTTCGGAGTTTGGGTTTGCTT-3'
MIG 5'-GAGTGCAAGGAACCCCAGTAGT-3' 5'-TTGTAGGTGGATAGTCCCTTGGTT-3'
IP-10 5'-TTCAAGGAGTACCTCTCTCTAG-3' 5'-CTGGATTCAGACATCTCTTCTC-3'
CXCL11 5'-CAAACATGAGTGTGAAGGGC-3' 5'-ATGCAAAGACAGCGTCCTCT-3'
CCL19 5'-CCTGCTGGTTCTCTGGACTT-3' 5'-CTCACGATGTACCCAGGGAT-3'
IL-8 5'-TGCCAAGGAGTGCTAAAG-3' 5'-CTCCACAACCCTCTGCAC-3'
CCL, C-C chemokine ligand; CXCL, C-X-C chemokine ligand; IFIG, IFN-inducible gene; IFIT, interferon-induced protein with tetratricopeptide 
repeats; IL, interleukin; IP-10, interferon-inducible protein 10; Ly6e, lymphocyte antigen 6 complex, locus E; MCP, monocyte chemotactic protein; 
MIG, monokine induced by interferon-γ; Mx1, myxovirus resistance 1; OAS, oligoadenylate synthetase; RANTES, regulated upon activation normal 
T-cell expressed and secreted.Available online http://arthritis-research.com/content/10/5/R112
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groups of patients chemokine scores were significantly higher
in patients with active LN than in those with inactive LN or with-
out LN (P = 0.014 and P = 0.002, respectively; Figure 3b),
indicating that chemokine scores are associated with ongoing
renal inflammation.
We also investigated the association between chemokine
scores and both chronic and irreversible tissue damage in
SLE, comparing scores between SLE patients with different
levels of chronic damage, as assessed using SDI. Results
revealed significantly elevated chemokine scores in SLE
patients with SDI scores of 1 to 2 and those with scores above
2 versus those without tissue damage (P = 0.010 and P <
0.05, respectively; Figure 3c). When patients with a pred-
nisone dose under 30 mg/day were selected, those with an
SDI score of 1 to 2 had significantly higher chemokine scores
than did those with no damage (P = 0.039). Although there
was only one patient in this lower dose prednisone analysis
with SDI above 2 (which therefore prevented statistical analy-
sis), the chemokine score of this single patient (SDI score = 6)
did appear inordinately high relative to all others (Figure 3d).
These data suggest that chemokine scores are associated
with cumulative organ damage in SLE, and that such a score
might be useful in predicting long-term outcomes in SLE
patients.
In order to investigate whether the chemokine score is respon-
sive to treatment and changes over time in conjunction with
disease activity, we selected four SLE patients who had initial
onset of biopsy-proved type IV LN and collected peripheral
blood samples at the beginning of treatment and after 3
months of treatment. Three of the patients (patient 1, 3 and 4)
used high-dose predisone(1 mg/kg per day) plus monthly
pulse of cyclophosphamide (0.8 g/month), whereas the other
(patient 2) used predisone plus mycophenolate mofetil (1.5 g/
day). After 12 weeks of treatment, two patients (patients 1 and
2) achieved clinical renal remission, with the urinary protein
level dropping to less than 0.5 g/24 hour and their daily dos-
age of predisone tapering to 35 mg. Patient 3 also had great
improvement in LN, with dramatic decreases in her urinary pro-
tein level (from 6.5 g/24 hours to 0.8 g/24 hours). In concord-
ance with the clinical improvement in nephritis, chemokine
scores in these three patients also significantly lowered. In
contrast, patient 4 did not respond to therapy and progressed
rapidly to renal failure despite aggressive treatment, including
repeated pulses of glucocorticoid (500 mg intravenous meth-
ylprednisolone) and cyclophosphamide therapies. Three
months after the first blood draw, the patient was suffering
from severe oedema and ascites, as well as aggravated renal
and heart failure. In parallel, the chemokine score in her periph-
eral blood leucocytes was dramatically elevated compared
with baseline (Figure 3e). The patient's condition worsened
rapidly and she died a month later. This result, although prelim-
inary, suggests that escalation in chemokine score may predict
an unfavourable outcome.
Figure 1
Comparison of chemokine and IFN scores between SLE and RA  patients, and healthy donors Comparison of chemokine and IFN scores between SLE and RA 
patients, and healthy donors. The methods employed to calculate the 
chemokine score and the IFN score are described in Materials and 
methods. (a) Chemokine scores were significantly elevated in SLE 
patients versus RA patients and healthy donors. (b) IFN scores were 
significantly elevated both in SLE and RA patients versus healthy 
donors. (c) Chemokine scores were positively correlated with IFN 
scores in SLE patients. Each symbol represents an individual patient; 
horizontal lines indicate median values. IFN, interferon; RA, rheumatoid 
arthritis; SLE, systemic lupus erythematosus.Arthritis Research & Therapy    Vol 10 No 5    Fu et al.
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Although chemokine scores and IFN scores appear to be
linked, we did not find significant differences in the mean value
of IFN scores between patients with various levels of SDI (P =
0.27; data not shown). This finding added additional credence
to the use of chemokine scores as a novel biomarker for SLE.
Association of chemokine scores with clinical features in 
SLE
To assess associations between chemokine scores and clini-
cal manifestations, autoantibody profiles and medication use,
the chemokine scores were compared between patients with
versus those without certain clinical features. We identified no
significant differences in chemokine scores between patients
with versus those without rash, mucosal ulcer, arthritis, serosi-
tis, and either neurological or haematological manifestations of
SLE (Table 3). However, chemokine scores did appear to be
associated with autoantibody production, being elevated in
patients with anti-Sm antibodies (median = 11.56, IQR = 3.89
to 23.82;P = 0.021) or anti-RNP antibodies (median = 10.28,
IQR = 3.08 to 18.97; P = 0.021; Table 3). In contrast to these
results, the presence of anti-dsDNA or anti-Ro antibodies was
not significantly associated with chemokine score (Table 3).
When medical therapies were considered, chemokine scores
were significantly decreased in patients on antimalarial drugs
at the time of blood donation (median = 2.15, IQR = -1.72 to
+12.11; P = 0.048; Table 3). Chemokine scores also exhib-
ited a trend toward being lower in patients receiving medium
to high doses of prednisone (>30 mg/daay; median = 4.76,
IQR = -1.56 to +12.66; P > 0.05). Treatment with immuno-
suppressive agents was not associated with elevated or
depressed chemokine scores (Table 3).
Discussion
In the present study, we selected seven IFN-inducible chem-
okines (RANTES, MCP-1, CCL19, MIG, IP-10, CXCL11 and
IL-8), and we investigated the associations between their com-
bined expression level and specific clinical features of SLE. Of
these seven chemokines, MCP-1, RANTES and CCL19 are
members of the CC family, and preferably recruit monocytes,
macrophages, T cells and dendritic cells. In contrast, MIG, IP-
10, CXCL11 and IL-8 are from the CXCL family, the first three
of which are chemoattractants of activated T cells, whereas IL-
8 is chemotactic for neutrophils [8]. All of these chemokines
have been reported to have consensus sequences for IFN-
responsive elements, including ISRE (IFN-stimulated respon-
sive element), GAS (IFN-γ activation site) and IRF (interferon
Figure 2
Association of chemokine and IFN scores with disease activity in SLE patients Association of chemokine and IFN scores with disease activity in SLE patients. Each symbol represents an individual patient; horizontal lines indicate 
median values. (a) SLE patients with a moderate-to-severe flare of disease (SLEDAI-2K score > 10) had significantly higher chemokine scores than 
did those without a disease flare (SLEDAI-2K score < 4) at the time of blood donation. (b) Chemokine scores were positively correlated with 
SLEDAI-2K. (c) Chemokine scores were significantly elevated in SLE patients with a reduced level of complement C3 (<80 mg/dl) compared with 
those with normal levels of C3. (d) A significantly negative correlation was observed between the chemokine score and C3 level. In addition, IFN 
scores were also correlated (e) positively with SLEDAI-2K and (f) negatively with C3 level. IFN, interferon; RA, rheumatoid arthritis; SLE, systemic 
lupus erythematosus; SLEDAI-2K, SLE Disease Activity Index 2000.Available online http://arthritis-research.com/content/10/5/R112
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regulatory factor), within their gene promoter regions [19-22].
Consequently, the expression levels of these chemokines can
be regulated by the IFN pathway, making them IFN inducible.
These chemokines have been studied extensively, and their
contributions to SLE have been confirmed by several different
investigative teams [23-26].
Rather than focusing on individual chemokines, as most previ-
ous investigators have done, we investigated the expression of
multiple chemokines and assessed the impact that overall
chemokine expression has on SLE disease features. We
measured the transcription levels of these chemokines in
peripheral leucocytes and calculated a chemokine score by
combining their expression levels. Given that there are various
sources of serum chemokines, other than those produced by
peripheral blood leucocytes, measurement of the mRNA levels
of these chemokines in peripheral blood cells is possibly a
direct indicator of the dysregulation of chemokine expression
that exists in peripheral immune cells in patients with SLE.
Moreover, the method is simple, inexpensive and has high
throughput, making it a suitable approach to gaining an over-
view of the expression of multiple chemokines.
In the SLE patients included in the study, IFN score was sig-
nificantly correlated with chemokine scores (Figure 1c), imply-
ing that expression levels of the IFN-inducible chemokines are
associated with those of classical IFIGs in SLE. This result,
however, was difficult to interpret because we did find ele-
vated chemokine scores in some SLE patients with a low IFN
score (IFN-low) and low chemokine scores in patients with a
high IFN score (IFN-hi). In addition, we found that the overall
chemokine score was significantly higher in SLE patients than
in RA patients or healthy donors (Figure 1a), whereas IFN
score was elevated in both of the disease groups compared to
healthy donors. This result verifies previous reports that IFIGs
are notably elevated in a subgroup of RA patients [27] but fails
to identify any increase in the expression of IFN-inducible
chemokines in RA, indicating that an elevated chemokine
score might be more specific for SLE than for RA.
One of the potential explanations for the discrepancy between
the expression of IFIGs and IFN-inducible chemokines is the
highly complicated regulation of chemokine expression that
exists in various diseases. Stimuli other than type I IFNs, such
as IL-18 or IL-2, as suggested by previous studies [10,13],
may be playing a role in driving the expression of chemokines
in SLE. Moreover, medication used by the patients at the time
Table 3
Chemokine scores by presence or absence of SLE clinical features
Clinical features SLE clinical features present SLE clinical features absent P
n Median (interquartile range) n Median (interquartile range)
Renal 36 8.32 (1.43 to 19.41) 31 3.39 (-1.43 to +12.48) NS
Neurological 4 1.27 (-0.65 to +4.17) 63 6.23 (-0.42 to +15.60) NS
Arthritis 12 5.09 (-2.48 to +13.98) 55 5.93 (0.12 to 14.01) NS
Serositis 13 5.47 (0.67 to 38.08) 54 5.32 (-0.93 to +13.96) NS
Rash 22 2.37 (-2.27 to +13.96) 45 7.39 (0.89 to 15.634) NS
Mucosal ulcer 8 4.21 (1.95 to 14.33) 59 5.93 (-4.46 to +14.01) NS
Haematological 19 7.39 (-2.77 to +13.91) 48 5.09 (0.59 to 14.81) NS
Proteinuria 26 8.511 (2.01 to 23.25) 41 3.39 (-1.56 to +12.56) NS
Autoantibodies
Anti-dsDNA 37 5.47 (-0.32 to +14.17) 30 5.72 (-0.44 to +14.81) NS
Anti-Ro 24 6.05 (1.85 to 13.96) 43 5.47 (-1.76 to +15.69) NS
Anti-Sm 13 11.56 (3.89 to 23.82) 54 3.56 (-1.72 to +12.66) 0.0211
Anti-RNP 23 10.28 (3.08 to 18.97) 44 2.95 (-1.72 to +12.56) 0.0212
Anti-nucleosome 24 7.50 (1.63 to 15.69) 43 3.73 (-0.46 to +13.91) NS
Medical therapy
Predisone dose >30 mg/day 38 4.76 (-1.56 to +12.66) 29 7.72 (2.12 to 19.89) NS
Immunosuppressants 28 9.98 (0.53 to 17.33) 39 3.08 (-1.43 to +12.65) NS
CQ/HCQ 28 2.15 (-1.72 to +12.11) 39 8.92 (2.34 to 18.97) 0.0481
anti-dsDNA, anti-double-stranded DNA; CQ, chloroquine; HCQ, hydrochloroquine; NS, not significant; SLE, systemic lupus erythematosus.Arthritis Research & Therapy    Vol 10 No 5    Fu et al.
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of blood donation may elicit different responses in the expres-
sion of chemokines or IFIGs. The use of multiple drugs (and
probably different drugs) by patients in the two patient groups
might also complicate data interpretation. Nevertheless,
regardless of the precise mechanism, these data suggest that
the chemokine score we present here, although closely linked
to IFN score, is an independent index for research and has
novel and specific clinical significance.
In the present study we found that chemokine scores were
associated with disease activity, as assessed using the
SLEDAI-2K score and C3 level, and with ongoing or cumula-
tive organ damage, as assessed based on the presence of
active LN or SDI score in SLE patients. An elevated chemok-
ine score may thus be helpful to identify SLE patient with
active and severe disease. The preliminary longitudinal data
also show that these chemokine scores are responsive to
treatment and may change in conjunction with disease activity
and severity, suggesting that chemokine score might be used
to monitor disease progression and guide therapy. One of the
weaknesses of the SLEDAI-2K score is its insensitivity in
detecting improvement or worsening in a manifestation,
because this can only be recorded as absent or present. For
example, although patient 3 (see Figure 3e) had a dramatic
decrease in urinary protein level from 6.5 g/24 hours to 0.8 g/
24 hours, the SLEDAI-2K score failed to capture the improve-
ment because she was still scored as positive in the proteinu-
ria category. Her chemokine score, however, exhibited a
significant decrease in concordance with the clinical improve-
ment. This result, although limited and preliminary, lent further
support to the chemokine score as a new and valuable marker
of SLE disease activity and severity. However, prospective lon-
Figure 3
Elevated chemokine scores in SLE patients with organ damage Elevated chemokine scores in SLE patients with organ damage. Each symbol represents an individual patient; horizontal lines indicate median val-
ues. (a) Chemokine scores exhibited a positive trend toward elevation in patients with active lupus nephritis (LN; n = 26) relative to patients with 
inactive LN (n = 10) and those with no history of LN (n = 31). (b) In the cohort, 30 patients were receiving daily doses of prednisone under 30 mg at 
the time of blood draw. Among them, eight patients had current LN, seven had inactive LN and 15 had never experienced renal manifestations of 
SLE. Patients with active renal disease had significantly higher chemokine scores than those with inactive LN or without LN. (c) Chemokine scores 
were significantly elevated in SLE patients with chronic and irreversible organ damage (SDI score 1 to 2 or more) compared with those with no dam-
age. (d) Among those patients whose daily dosage of prednisone was less than 30 mg, chemokine scores were also significantly higher in those 
with versus those without chronic organ damage. (e) Chemokine scores were calculated in four active LN patients at the beginning of and after 12 
weeks of treatment. In patient (p) 1, p2 and p3 (who achieved significant clinical improvement after treatment) chemokine scores were notably 
decreased, whereas in p4 (who had rapidly progressed into renal failure) chemokine score was dramatically increased. LN, lupus nephritis; SDI, Sys-
temic Lupus International Collaborating Clinics/American Society of Rheumatology Damage Index; SLE, systemic lupus erythematosus.Available online http://arthritis-research.com/content/10/5/R112
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gitudinal studies with a larger sample size and more visits are
needed to assess the role of chemokine score as a reliable
biomarker in SLE.
Our conclusion that increased overall production of IFN-induc-
ible chemokines by peripheral blood cells is important in the
pathogenesis of SLE is supported by a number of published
papers. Chemokines may contribute to SLE by recruiting
immune and inflammatory cells to target tissues and by altering
the normal trafficking and localization of certain populations of
immune cells in the body; hence, they may impair the normal
function of such cells. In cutaneous lupus erythematosus, MIG
and IP-10 have been found to be significantly upregulated in
inflamed skin and to help in the recruitment of plasmacytoid
dendritic cells (pDCs), the major producers of type I IFN, to the
skin [28]. This result could explain, at least in part, the obser-
vation that the number of pDCs is reduced in the peripheral
blood of SLE patients [29], and that pDCs are recruited into
and enriched within inflamed target tissues [30,31]. Moreover,
ectopic expression of CCL19 can retain dendritic cells in tar-
get tissue and prevent their normal homing and migration to
lymph nodes [32]. Previous investigators have reported that
systemic over-expression of MCP-1 in mice can impair the
homing and migration of monocytes to a localized MCP-1 gra-
dient [33], and that MCP-1 may inhibit the normal differentia-
tion of monocytes, which is possibly one of the mechanisms
that is involved in autoimmunity [34]. In confirmation of these
reports, our current data demonstrate that the overall produc-
tion of IFN-inducible chemokines, as measured using a chem-
okine score, may serve as a useful indicator of the ongoing
state of immune dysregulation in SLE.
In addition, in a small-scale study we also observed that the
expression levels of those IFN-inducible chemokines were
notably elevated in CD14+ monocytes compared with T and B
lymphocytes from SLE patients, indicating that monocytes
might be more important contributors to the chemokine score
than lymphocytes (data not shown). Therefore, the number as
well as the activation state of the circulating monocytes might
be a valuable clinical marker in SLE. In accordance with this
assumption, it was recently reported [35] that activated renal
macrophages are markers of disease onset and remission in
LN, adding the possibility that active circulating monocytes
might also be useful in disease monitoring in SLE. However,
additional studies are needed in this area.
The patients with anti-Sm or anti-RNP autoantibodies had
higher chemokine scores than did SLE patients without these
two autoantibodies. An association of chemokine score with
anti-Sm and anti-RNP antibodies is, to our knowledge,
reported here for the first time. The underlying pathophysiolog-
ical mechanism for this remains unknown. One possible expla-
nation, however, is that the expression of IFN-inducible
chemokines is somewhat linked to the IFN signature. The
association between the IFN signature and anti-RNP autoanti-
bodies was reported in earlier studies [5,6,36]. Although the
mechanisms are unclear, it has been proposed that activation
of pDCs by single-stranded or double-stranded RNA, through
Toll-like receptors, might lead to the induction of type I IFN pro-
duction and enhanced presentation of RNA-associated mate-
rials to autoreactive T and B cells. This, in turn, has the
potential to cause upregulation of IFIGs and the appearance
of anti-RNA-associated protein autoantibodies. Given that
patients who are positive for anti-Sm or anti-RNP antibodies
exhibit increased IFN scores, it is not surprising that such
patients also have higher expressions of IFN-inducible chem-
okines and exhibit higher chemokine scores.
Conclusion
The present study provides new evidence that IFN-inducible
chemokine gene transcript levels in peripheral blood leuco-
cytes may act as a new and reliable marker for disease activity
and organ damage in human SLE. The data also suggest that
the type I IFN system may contribute to SLE by modulating the
expression of chemokines, linking these two networks in the
pathogenesis of SLE. Additional studies are required to eluci-
date the highly complex interactions between IFIGs and chem-
okines, especially within the context of specific autoimmune
diseases. The findings of such studies will shed new light on
the dysregulation of the immune system and the involvement
of inflammation in the initiation and perpetuation of
autoimmunity.
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